Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
PR Newswire•13/10/2026•07:00 ET
0
Key Highlights
- ➤$5.1 million committed development and clinical manufacturing agreement signed
- ➤Committed Customer Orders reach $7.6 million, up approximately 300% from year-end 2025
- ➤Clinical manufacturing program planned to begin in January 2027
- ➤Potential additional clinical manufacturing valued at $5.85 million, uncommitted
- ➤Services include CMC development, IND-enabling work, and oncology-product manufacturing
Expert Statements
Amir Reichman, Chief Executive Officer of Scinai
“This agreement materially expands our contracted CDMO business and supports our strategy of delivering high-quality, bespoke CDMO services to international customers.”
Amir Reichman, Chief Executive Officer of Scinai
“It provides greater visibility into our manufacturing workload for 2027 and combines development and IND-enabling activities underway in 2026 with a clinical manufacturing program planned to begin in January 2027.”
Amir Reichman, Chief Executive Officer of Scinai
“Our priority is to translate these commitments into revenue, increased facility utilization and stronger operating performance, while continuing to aggressively grow the business.”
Amir Reichman, Chief Executive Officer of Scinai
“The potential for additional clinical supply and, ultimately, commercial manufacturing illustrates how these customer relationships can develop over time.”
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement PR Newswire
Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025
Get started
Create a free account to read the full story.